Recombinant anti-HER2 humanized monoclonal antibody (Shenzhen Main Luck Pharmaceuticals)

重组抗HER2人源化单抗（深圳万乐药业）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant anti-HER2 humanized monoclonal antibody (Shenzhen Main Luck Pharmaceuticals)
Drug Alias Name注射用重组抗HER2人源化单抗（深圳万乐药业）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Main Luck Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Main Luck Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A